Apitope is a European biotech company
Apitope is a biotech company focused on the discovery and development of disease modifying therapies for autoimmune and allergic diseases, including multiple sclerosis, Graves’ disease, Factor VIII intolerance and uveitis. The company, whose first product candidate is licensed to Merck Serono, will now progress its remaining portfolio of product candidates developed with its proprietary platform technology.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Sep 29, 2015 | Series B | €12M | 1 | — | — | Detail |
Oct 30, 2008 | Series A | €10M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Wyvern Seed Fund | — | Series B |
Vinnof | — | Series A |